Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:42 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Phase I Trial of LDE225 for Steroid-refractory Chronic GVHD After Allogeneic HSCT
NCT02086513 · Massachusetts General Hospital · PHASE1 · terminated · last registry update 2018-03-19 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Massachusetts General Hospital |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SMO within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2019-03-08Results posted on the registry: Anne Chang, Pembrolizumab + Vismodegib (NCT02690948)
- 2019-03-07Results posted on the registry: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, LDE225 (NCT02111187)
- 2019-02-28Results posted on the registry: National Cancer Institute (NCI), Goserelin Acetate + Leuprolide Acetate (NCT01163084)
- 2019-02-28Also stopped (terminated): National Cancer Institute (NCI), Goserelin Acetate + Leuprolide Acetate (NCT01163084)
- 2019-01-29Results posted on the registry: Anne Chang, Buparlisib + Sonidegib (NCT02303041)
- 2019-01-29Also stopped (terminated): Anne Chang, Buparlisib + Sonidegib (NCT02303041)
- 2019-01-17Also stopped (terminated): Pfizer, Glasdegib (PF-04449913) + Placebo (NCT02226172)
- 2019-01-04Results posted on the registry: PellePharm, Inc., Patidegib + Vehicle gel (NCT02828111)
- 2018-12-28Results posted on the registry: Eli Lilly and Company, LY2940680 + Carboplatin (NCT01722292)
- 2018-12-28Also stopped (terminated): Eli Lilly and Company, LY2940680 + Carboplatin (NCT01722292)
- 2018-12-21Phase 3 first posted: Institut National de la Santé Et de la Recherche Médicale, France, Nilotinib + Ceritinib (NCT03784014)
- 2018-12-04Results posted on the registry: Spanish Breast Cancer Research Group, LDE225 + Docetaxel (NCT02027376)
- 2018-11-13Results posted on the registry: Stanford University, Itraconazole (NCT01108094)
- 2018-10-11Phase 3 first posted: Sol-Gel Technologies, Ltd., Patidegib Topical Gel, 2% + Patidegib Topical Gel, Vehicle (NCT03703310)
- 2018-07-20Results posted on the registry: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Vismodegib (NCT02115828)
- 2018-05-23Results posted on the registry: Pfizer, PF-04449913 + Low dose ARA-C (LDAC) (NCT01546038)
- 2018-04-02Results posted on the registry: Pfizer, Glasdegib (PF-04449913) + Placebo (NCT02226172)
- 2018-01-31Phase 3 first posted: Pfizer, glasdegib + daunorubicin + cytarabine (NCT03416179)
- 2017-10-02Results posted on the registry: Stanford University, vismodegib (NCT01631331)
- 2017-08-16Results posted on the registry: National Cancer Institute (NCI), vismodegib (NCT00980343)
- 2017-06-14Results posted on the registry: Novartis Pharmaceuticals, LDE225 + TMZ (NCT01708174)
- 2017-05-08Results posted on the registry: Hoffmann-La Roche, Placebo + Vismodegib (NCT01898598)
- 2017-05-08Also stopped (terminated): Hoffmann-La Roche, Placebo + Vismodegib (NCT01898598)
- 2017-05-05Also stopped (withdrawn): Novartis Pharmaceuticals, LDE225B + Vehicle (NCT03070691)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision